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IntroductIon
The evolutionarily conserved GP130 cytokine receptor su-
perfamily mediates interactions between a wide range of 
immune and nonimmune cells (Sims, 2009; O’Shea and 
Plenge, 2012). GP130 can bind several distinct receptor sub-
units such as IL-6RΑ, IL-11RA, leukemia inhibitory factor 
(LIF) receptor, oncostatin M (OSM) receptor, or ciliary neu-
rotrophic factor (CNTF) receptor, facilitating recognition 
of multiple ligands including IL-6, IL-11, IL-27, LIF, OSM, 
CNTF, cardiotrophin 1 (CT1), and cardiotrophin-like cyto-
kine (CLC). Signal transduction via GP130 is mediated by 
the JAK/STAT pathway and includes phosphorylation of 
STAT3 and STAT1, as well as activation of RAS/MAPK 
(O’Shea and Plenge, 2012).
An essential role for GP130-dependent signaling is 
shown by the lethality of the corresponding homozygous KO 
(Il6st−/−) in mice, caused by myocardial and hematological 
defects (Yoshida et al., 1996). In addition, GP130-deficient 
mice have multiple skeletal abnormalities because of a fail-
ure in osteoblast and osteoclast function (Kawasaki et al., 
1997; Shin et al., 2004). Mice with a conditional, postnatal 
KO of GP130 develop emphysema, infection susceptibility 
because of defective IL-6 signaling, liver and heart damage, 
and a dysfunctional acute-phase response (Betz et al., 1998). 
Similarly, loss of function of the downstream signal trans-
ducer STAT3 is embryonically lethal in mice (Takeda et al., 
1997), whereas hypomorphic STAT3 variants cause immune 
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dysregulation (Steward-Tharp et al., 2014), and conditional 
osteoblast-specific ablation leads to reduced bone forma-
tion (Itoh et al., 2006).
In humans, autosomal-dominant (AD) hyper-IgE syn-
drome (HIES), caused by dominant-negative STAT3 mu-
tations, is a complex immunodeficiency that presents with 
pneumonia, lung abnormalities, high levels of IgE, eosin-
ophilia, eczema, and skeletal and connective tissue abnor-
malities including retained primary teeth, scoliosis, and 
craniosynostosis (Smithwick et al., 1978; Höger et al., 1985; 
Gahr et al., 1987; Grimbacher et al., 1999a, 2005; Holland et 
al., 2007; Minegishi et al., 2007; Miller et al., 2017). Other 
syndromes associated with marked IgE elevation and im-
mune deficiency include DOCK8 deficiency (Engelhardt 
et al., 2009; Zhang et al., 2009) and PGM3 deficiency (Sassi 
et al., 2014; Zhang et al., 2014). Defects in TYK2 seem 
to be only rarely associated with HIES (Minegishi et al., 
2006; Kreins et al., 2015).
Recently, recessive loss-of-function mutations of 
IL11RA, encoding IL-11RA, were identified in patients 
with craniosynostosis and dental anomalies (CRS DA; On-
line Mendelian Inheritance in Man accession no. 614188; 
Nieminen et al., 2011; Keupp et al., 2013; Papachristoforou 
et al., 2013; Miller et al., 2017). The clinical features include 
multi-suture craniosynostosis, maxillary hypoplasia, delayed 
tooth eruption, supernumerary teeth, and minor digit abnor-
malities. Mutant mice have increased trabecular bone volume 
with defective differentiation of osteoclast precursors (Sims 
et al., 2005), whereas the delayed tooth eruption found in 
individuals with IL11RA mutations is probably caused by re-
duced bone resorption in the jaw.
Here, we identify a patient with a causative homozygous 
mutation in IL6ST, encoding the human cytokine receptor 
subunit GP130, presenting with immunodeficiency and skel-
etal abnormalities including craniosynostosis, and demonstrate 
associated defects in IL-6, IL-11, IL-27, and OSM signaling.
rESuLtS And dIScuSSIon
Patient summary
The index patient 1 (P1), the female offspring of con-
sanguineous (first cousin) parents of south Asian origin 
(Fig. 1 A), presented with skeletal abnormalities, including 
severe craniosynostosis and progressive scoliosis (Fig. 1 B). 
From the age of 6 mo, she developed multiple early, severe, 
and complicated recurrent respiratory tract infections, in-
cluding pneumonia that needed antibiotic treatment, mul-
tiple hospitalizations, and intensive care. Then, the patient 
developed severe bronchiectasis and required oxygen sup-
plementation. At 1 yr of age, eye infections were apparent, 
and bilateral corneal ulcers were noted. Other severe in-
fections included periorbital cellulitis caused by group A 
Streptococci. She presented with eczema at the age of 2 yr 
as well as increasingly high IgE levels (maximum >5,000 
IU/ml) and intermittent eosinophilia (for immunological 
characteristics of P1, see Tables 1, 2, and 3). This is reflected 
by a high NIH HIES score (Grimbacher et al., 1999b) of 
40. A detailed patient history is provided in Materials and 
methods. No other family members were affected.
Identification of IL6St mutation and prediction 
of the mutational impact
Initial genetic investigation for causes of craniosynostosis, 
including sequencing of fibroblast growth factor receptor 
1 (FGFR1), FGFR2, and FGFR3, and array comparative 
genomic hybridization yielded negative results. Exome se-
quencing of DNA did not identify known genetic causes 
of craniosynostosis (Miller et al., 2017). Assuming a reces-
sive mode of inheritance and homozygosity of the caus-
ative mutation, the exome data identified 29 regions with 
homozygous stretches >5 Mb (not depicted). In total, 
there were 375 homozygous variants (with ≥4 variant 
reads). After removal of synonymous variants and changes 
found within in-house exome-sequencing data, 49 non-
synonymous variants remained (Table S1). The top ranking 
candidate (determined by six predictors of the functional 
effect of amino acid substitutions; Fu et al., 2013) was a 
homozygous variant (c.1210A>T) in IL6ST, predicting a 
substitution of tyrosine for asparagine (p.N404Y). Dideoxy 
sequencing of samples from the family showed that both 
parents were heterozygotes and that the variant segregated 
in a homozygous state only to P1 but not to the other two 
healthy siblings (Fig. 1 C).
The c.1210A>T variant was not present in any database 
(including National Heart, Lung, and Blood Institute Exome 
Variant Server, INT ERV AL cohort, UK10K consented ex-
omes, 1,000 Genomes, Exome Aggregation Consortium 
[ExAC] v0.3.1, and gnomAD) covering >120,000 exomes 
or genomes and different populations. The amino acid N404 
in GP130 is evolutionary highly conserved across species as 
well as across related cytokine receptors such as IL-27RA/
WSX1, IL-12RB1, and GCSF-R encoded by CSF3R 
(Fig. 1 D; Xu et al., 2010), suggesting a conserved structural 
role of this residue. p.N404Y is predicted to be damaging 
by several scores including SIFT and Polyphen2 (Table S1). 
No other predicted pathogenic mutations were detected in 
candidate genes such as IL6RA, STAT3, TYK2, IL11RA, or 
IL27RA. A homozygous variant was detected in DOCK8. 
However, it was considered unlikely to be a major contribu-
tor to the phenotype (Table S1).
The constraint metric for IL6ST based on the ExAC 
dataset (probability of loss-of-function intolerance [pLI] 
= 0.995) indicates strong selection against predicted 
loss-of-function mutations (Fig. 1 E; Lek et al., 2016). No 
deletions or pathogenic variants in IL6ST are annotated in 
the CLI NVAR database. In contrast, IL6ST variants pre-
dicting GP130 gain of function have been described in 
several tumors, in particular hepatocellular adenomas (Pi-
lati and Zucman-Rossi, 2015). However, the p.N404Y sub-
stitution is absent in the Catalog of Somatic Mutations in 
Cancer (COS MIC) database.
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resequencing of IL6St and exome screening
In an effort to identify additional cases, we screened IL6ST 
for homozygous or compound heterozygous variants ei-
ther by direct resequencing (467 patients with craniosyn-
ostosis, mutation negative for the major known causes) 
or by interrogation of existing exome data (207 patients 
with HIES or chronic mucocutaneous candidiasis; 35 pa-
tients from 25 families with HIES and skeletal abnormali-
ties; summarized in Fig. 1 F). No convincingly pathogenic 
rare homozygous or compound heterozygous variants were 
found in these cohorts.
differential effects of GP130 variants on IL-6, IL-11, 
IL-27, oSM, and LIF signaling
To compare the in vitro effects of the likely pathogenic 
p.N404Y variant on signaling of different cytokines that 
require GP130, we created a GP130-deficient HEK293 
cell line (HEK293 GP130-KO) using CRI SPR/Cas9 (Fig. 
Figure 1. Genetic analysis of IL6St. (A) P1 showing pedigree and segregation of IL6ST alleles. Roman numerals (I or II) indicate generations, and Arabic 
numerals designate individuals (1, 2, or 3). Closed symbols identify the affected individual P1. (B, left) 3D computed tomographic reconstruction of skull of 
P1 showing pansutural synostosis. (Middle) Posteroanterior radiograph at age 2.8 yr demonstrating scoliosis. (Right) Chest radiograph at age 3.9 yr showing 
pneumonia, bronchiectasis, and scoliosis. (C) Dideoxy sequencing of P1 family, showing segregation of the c.1210A>T variant (red arrow). The box encloses 
the asparagine codon. (D) Alignment of GP130 protein sequence showing conservation of amino acid p.N404 among species (top) and across the class of tall 
cytokine receptors (bottom). Substitution to tyrosine (Y) is shown between the panels. (E) pLI of 17,739 human genes based on ExAC data. IL6ST and STAT3 
genes are highlighted indicating their strong intolerance to loss-of-function variation. (F) Screening strategy within cohorts of patients with craniosynos-
tosis and/or immunodeficiency (HIES and mucocutaneous candidiasis). A homozygous c.842G>A; p.R281Q substitution identified in the craniosynostosis 
cohort was classified as a variant of unknown significance and is not further discussed.
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S1, A–E). This cell line does not phosphorylate STAT1 or 
STAT3 in response to stimulation with IL-6 (Fig. S1, D and 
E), IL-11, IL-27, OSM, or LIF (not depicted) but has nor-
mal STAT3 signaling in response to type 1 IFN and normal 
STAT1 in response to IFN-γ (Fig. S1 E). Transfection with 
GP130 WT restores GP130-dependent signaling (Fig.  2). 
We excluded differences between the surface expression of 
GP130 WT and the variant p.N404Y by flow cytometry, 
suggesting that p.N404Y does not cause mRNA or pro-
tein instability (Fig. S1 F). Titration studies on transfected 
GP130-KO cells revealed that the variant showed an absent 
STAT3 phosphorylation in response to IL-11 stimulation 
(Fig. 2 A) and significantly reduced STAT3 phosphorylation 
after stimulation with IL-6, IL-27, or OSM (Fig. 2, B–D). 
Interestingly, the LIF response was largely intact (Fig. 2 E). 
The p.N404Y variant also exhibited defective IL-11– 
induced STAT1 phosphorylation and a reduced STAT1 re-
sponse to IL-6 or IL-27 (Fig. 2 F).
Table 1. Lymphocyte subsets of P1 (p.n404Y)
1.9 yr of age 5 yr of age 6.1 yr of age
Patient Reference range Patient Reference range Patient Reference range
Absolute lymphocyte count (G/liter) 7.4 2.7–11.9 4.5 1.7–6.9 3.9 1.1–5.9
CD3+ T cells (cells/μl) 4,600 1,400–8,000 2,831 900–4,500 2,876 700–4,200
 CD3+HLA-DR+ (%) 6 3–13 16 3–14
CD4+ T cells (cells/μl) 3,030 900–5,500 1,716 500–2,400 1,244 300–2,000
 CD45RA+CCR7+ (%) 78.5 57.4–84.9
 CD45RA−CCR7+ (%) 9.8 11.3–26.7
 CD45RA−CCR7− (%) 9.1 3.3–15.2
 CD45RA+CCR7− (%) 1.7 0.4–2.6
CD8+ T cells (cells/μl) 1,570 400–2,300 1,009 300–1,600 1,459 300–1,800
 CD45RA+CCR7+ (%) 44.9 28.4–80.6
 CD45RA−CCR7+ (%) 1 1–4.5
 CD45RA−CCR7− (%) 6.7 6.2–29.3
 CD45RA+CCR7− (%) 43.1 9.1–49.1
CD4/CD8 1.9 1–3 1.7 1–2.1 0.85 0.9–2.6
CD56+CD16+ NK cells (cells/μl) 110 61–510 99 70–590 231 70–590
CD19+ B cells (cells/μl) 1,560 529–1,930 1,532 323–1,000 788 212–796
 CD27−IgD+ naive (%) 96 70–86 93 63–89
 CD27+IgD+ nonswitched memory (%) 3 7–15 3 3–19
 CD27+IgD− class-switched memory (%) 1 4–16 3 4–17
Abnormal results are shown in bold.
Table 2. Immunoglobulins and serum antibody responses of P1 (p.n404Y)
1.2 yr of age 1.8 yr of age 5 yr of age 6.1 yr of age
Patient Reference range Patient Reference range Patient Reference range Patient Reference range
IgG (g/liter) 11.5 3.45–12.13 7.81 4.24–10.51 7.8 4.63–12.36 10.45 6.33–12.80
IgA (g/liter) 1.65 0.14–1.06 0.84 0.14–1.23 0.25 0.25–1.54 0.31 0.33–2.02
IgM (g/liter) 1.86 0.43–1.73 1.23 0.48–1.68 1.07 0.43–1.96 0.85 0.48–2.07
IgE (IU/liter) 43 2–97 466 2–97 >5,000 2–307
Hib IgG (μg/ml) 6.64 0.16–40.8
Pneumococcal (titer)
IgG 1,280 640
IgG2 40 40
Tetanus antibody (IU/ml) 0.35 0.04–3.92
Abnormal results are shown in bold.
Table 3. Eosinophils and neutrophil respiratory burst in P1 (p.n404Y)
1.8 yr of age 6.1 yr of age
Patient Reference range Patient Reference range
Eosinophils (G/liter) 3.36 0.0–0.8 2.37 0.0-0.8
Neutrophil respiratory burst (DHR) 63 >40
Abnormal results are shown in bold.
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Figure 2. the GP130 p.n404Y substitution causes defective signaling by IL-11, IL-6, IL-27, oSM, and LIF. (A–E) HEK293 GP130-KO cells were 
transfected with empty vector control or plasmids encoding GP130 WT or the patient variant p.N404Y. Cells were stimulated with the indicated concentra-
tions (ng/ml) of IL-11 (A), IL-6 (B), IL-27 (C), OSM (D), or LIF (E) for 15 min and analyzed for STAT3 phosphorylation (p-STAT3) by Phosflow. For assessment of 
IL-11 and IL-6 signaling, cells were cotransfected with plasmids encoding IL-11RA and IL-6RA, respectively. Co-transfection with GFP allowed gating on suc-
cessfully transfected cells. Representative titration curves (on the left in each panel) are shown for each ligand and are representative of two independent 
experiments. Curve fitting is by nonlinear regression. Quantification (on the right in each panel) is based on four to six independent experiments per cytokine 
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Next, we used confocal microscopy to assess the impact 
of p.N404Y on IL-6–mediated STAT3 nuclear transloca-
tion. In p.N404Y-transfected HEK293 GP130-KO cells, we 
observed a defective cytoplasmic to nuclear STAT3 translo-
cation in response to IL-6 (Fig. 2 G). Furthermore, we in-
vestigated the functional consequences of GP130 p.N404Y 
in a STAT3 luciferase reporter assay. The p.N404Y variant 
caused defective luciferase induction after IL-6 and IL-11 
stimulation (Fig. 2 H).
We validated the defective signaling of the p.N404Y 
variant in response to IL-11 by Western blotting (not depicted). 
Pulldown experiments suggested that the signaling defect is 
not caused by defective heterodimerization of the GP130 
p.N404Y variant with IL-6RA or IL-11RA (not depicted).
defects in the IL-6 response in primary 
immune cells of GP130 p.n404Y
To investigate the functional consequences of the GP130 
p.N404Y substitution in primary immune cells, we stim-
ulated whole blood of P1 as well as controls with the 
GP130-dependent cytokines IL-6 and IL-27 for 15 min and 
measured STAT3 phosphorylation using intracellular stain-
ing and flow cytometry (Fig.  3). P1 displayed a complete 
loss of IL-6 signaling in primary T cells, B cells, and mono-
cytes (Fig. 3, A, C, and D). Immune cells from healthy do-
nors or a patient with a previously unpublished homozygous 
c.889G>T (p.D297Y; see the Case studies section of Material 
and methods for phenotype) mutation in IL11RA responded 
to IL-6 stimulation. We confirmed the defective IL-6 sig-
naling in P1-derived T lymphoblasts (Fig.  3  B) as well as 
EBV-transformed lymphoblastoid cell lines (LCLs; Fig. 3 C). 
Cellular responses to IL-27 were impaired in P1 (particu-
larly in monocytes) but not abolished (Fig. 3 D). Stimulation 
with IL-10 and IL-21, as controls for the induction of phos-
pho-STAT3, showed a normal response in P1 and controls.
Immunodeficiency caused by the p.n404Y substitution
To understand the immune defect in P1, we characterized 
leukocyte and lymphocyte subsets. The absolute numbers of 
T, B, and NK lymphocytes of P1 in the peripheral blood were 
largely normal, but a reduced fraction of class-switched mem-
ory B cells were noted (Table  1). The reduced proportion 
of memory B cells in P1 (Table 1) is reminiscent of patients 
with STAT3-HIES and patients treated with anti–IL-6R 
mAb tocilizumab (Roll et al., 2011) but is not seen in pa-
tients with atopic dermatitis and high IgE (Speckmann et al., 
2008; Meyer-Bahlburg et al., 2012). This confirms the role of 
IL-6 signaling for B cell memory. As an indication of a poten-
tially distinct differential B cell defect, in STAT3-HIES, poor 
pneumococcal antibody responses were described requiring 
intravenous immunoglobulin in 4 of 10 patients (Flinn et 
al., 2016), whereas in the p.N404Y GP130 patient, a normal 
pneumococcal response was noted (Table 2).
P1 presented with eosinophilia (maximum 3.36 Gpt/
liter) and high IgE (>5,000 IU/ml at 6.1 yr of age), whereas 
levels of IgM, IgG, and IgA were not affected, and levels of 
antibody to Haemophilus, Pneumococcus, and Tetanus were 
each within the normal range (Tables 2 and 3). Given the 
previously reported role of STAT3 signaling in generating 
IL-17–producing lymphocytes (de Beaucoudrey et al., 2008; 
Ma et al., 2008; Milner et al., 2008), we investigated the fre-
quency of T helper type 17 cells (Th17 cells) ex vivo. Within 
the compartment of CD4+CD45RA−CD25− memory T 
cells, we detected CCR6+, RORγt-expressing (not depicted), 
and IL-17A–producing cells (Fig. 3, E–G) and demonstrated 
the presence of in vivo–differentiated memory Th17 cells in 
P1 through the isolation of IL-17A–producing single-cell 
clones (Fig. 3 H). Together, these results are consistent with 
the absence of fungal infections in P1.
delayed or absent acute-phase response in P1
We noted that, despite severe bacterial infections with Staphy-
lococcus aureus (culture from cornea and lung), Streptococcus 
group A, or Streptococcus milleri that required intensive care 
and antibiotic treatment and led to repeated leukocytosis and 
neutrophilia, there was only a delayed and reduced acute phase 
response. Even with exceptionally high leukemic-like counts 
(peripheral blood white blood cells, 57 Gpt/liter; and neutrophil 
count, 46 Gpt/liter), only a moderate and delayed C-reactive 
protein (CRP) increase and no fibrinogen elevation were found 
in P1 (Fig. 4 A). Given that IL-6 is the major stimulus for the 
production of most acute-phase proteins (Gabay and Kushner, 
1999), we surmised that the p.N404Y mutation impairs the he-
patocyte response. To test this hypothesis in an in vitro model, 
we created an IL6ST/GP130 KO using CRI SPR/Cas9 in the 
human hepatoma cell line Hep3B and confirmed that these 
cells are defective in the IL-6–mediated induction of fibrinogen 
(Fig. 4, B and C). GP130-KO cells transfected with GP130-p.
N404Y were unable to up-regulate fibrinogen after stimulation 
with IL-6, whereas transfection of GP130-WT restored the re-
at one concentration (IL-11, 1 ng/ml; IL-6, IL-27, OSM, and LIF, all 100 ng/ml). (F) Experiments with HEK293 GP130-KO cells performed as in A–C. Cells were 
assayed for phospho-STAT1 (p-STAT1). Titration curves are representative of two independent experiments. MFI, mean fluorescence intensity. (G) Immuno-
fluorescence staining of HEK293 GP130-KO cells, plated in chamber slides and transfected as in A. Cells were analyzed for STAT3 nuclear translocation using 
confocal microscopy. Bars, 50 µm. Images on the right are merged and magnified. Images are representative for three independent experiments. (H) HEK293 
cells were cotransfected with luciferase (Luc) reporters, GP130 variants, and IL-11RA or IL-6RA expression vectors, respectively. After 24 h, cells were stimu-
lated with 1 ng/ml IL-11 (top) or 0.5 ng/ml IL-6 (bottom) for 6 h, and induction of STAT3 reporter (relative to constitutively expressed Renilla luciferase) was 
determined. Results are expressed as fold-induction compared with unstimulated vector control and are pooled data from three independent experiments 
with three to six technical replicates each. Data represent mean with SEM. Differences were investigated by Mann-Whitney U test. **, P < 0.01; ***, P < 0.001.
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Figure 3. the GP130 p.n404Y substitution abrogates IL-6 signaling in primary t cells, B cells, and monocytes. (A–D) Primary immune cells 
were stimulated for 15 min with 100 ng/ml IL-6, 50 ng/ml IL-10, 100 ng/ml IL-21, or 100 ng/ml IL-27, and STAT3 phosphorylation (p-STAT3) was analyzed 
using intracellular staining and flow cytometry. Representative histograms are shown (blue, unstimulated; red, cytokine stimulated). Results show percent 
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sponse (Fig. 4 D). This finding suggests that a delayed or absent 
acute-phase response as a critical innate immune reaction toward 
bacterial infection contributes to the complex immunodefi-
ciency in P1. Acute-phase proteins such as CRP and fibrinogen 
bind to the bacterial surface and support opsonization, bacterial 
uptake, and killing (Gabay and Kushner, 1999). Mice deficient 
in fibrinogen are more susceptible to group A streptococcal in-
fections, and fibrinogen has direct antimicrobial activity (Påhl-
man et al., 2013). Early antibiotic therapy for ongoing infections 
is therefore required in P1, irrespective of normal, potentially 
false-negative CRP values, to avoid repeat bacterial lung infec-
tions causing secondary lung structural damage. Interestingly, a 
blockade of IL-6 signaling by therapeutic antibodies (Nguyen et 
al., 2013) or autoantibodies (Puel et al., 2008) was associated with 
severe bacterial infections and compromised CRP up-regulation, 
suggesting a shared clinical outcome of gram+ infection suscep-
tibility in IL-6 signaling defects.
the p.n404Y substitution causes stromal cell dysfunction 
and can be rescued by Wt GP130
Stromal cells express high levels of GP130 and respond to mul-
tiple cytokines. Fibroblasts of P1 showed absent or substantially 
reduced levels of phospho-STAT3 and phospho-STAT1 after 
IL-11 and IL-6 treatment, moderate reduction after IL-27 
and OSM stimulation, and a normal response pattern after 
LIF treatment (Fig. 4, E and F). Thus, our previous in vitro 
transfection assay with HEK293 GP130-KO cells (Fig. 2) re-
flects the response in patient-derived primary fibroblasts.
To confirm the causal relationship between the muta-
tion of GP130 p.N404Y and the defective cytokine response, 
we expressed WT GP130 in P1 fibroblasts by lentiviral trans-
duction. This rescued the impaired IL-6– or IL-11–mediated 
STAT3 phosphorylation (Fig. 4 G).
Structural impact of the mutations on 
binding of cytokine receptors
Next, we wanted to understand the structural mechanisms 
by which p.N404Y causes a differential defect in the signal-
ing of cytokines via GP130. Therefore, we investigated the 
published protein structures of the IL-6/IL6-RA/GP130 
hexamer complex (Fig. S2 A; Boulanger et al., 2003; Xu et 
al., 2010). The N404 residue in GP130 is not exposed at the 
surface but forms part of a β-turn that comprises N404, L405, 
V406, and G407 (Fig. S2 B). The amide group of N404 forms 
a network of hydrogen bonds, mainly with the backbone ox-
ygens of A359, N360, and G361 as well as with the backbone 
nitrogen atoms of V406 and G407 (Fig. S2 B). As these inter-
actions stabilize the β-turn, the p.N404Y exchange is likely 
to weaken the secondary structure by disruption of several 
hydrogen bonds to neighboring backbone atoms. Thus, as 
supported by our data, the pathogenicity of p.N404 might 
not be driven by aberrant interaction of specific receptor–
ligand pairs but rather by defective secondary and tertiary 
structure of the receptor.
Our data collectively show that a loss-of-function mu-
tation of IL6ST, encoding GP130 p.N404Y, results in a severe 
syndromic immunodeficiency with skeletal abnormalities and 
a pleiotropic defect in signaling by multiple cytokines (in-
cluding IL-6, IL-11, IL-27, and OSM), features that largely 
phenocopy AD-HIES because of loss-of-function STAT3 
mutations (Holland et al., 2007; Minegishi et al., 2007). The 
partially overlapping features between the GP130 p.N404Y 
patient and AD-HIES caused by STAT3 mutations inform 
and differentiate aspects of defective cytokine signaling. Aside 
from diminished IL-6 signaling, defects in IL-10, IL-21, and 
IL-23 signaling were suggested to explain aspects of HIES 
(Minegishi and Saito, 2011). For example, increased serum 
IgE and disturbed B cell differentiation were attributed to 
abnormal IL-21 signaling in STAT3-HIES, and IL-10 sig-
naling defects were associated with its immune dysregula-
tion (Minegishi and Saito, 2011). Our findings now restrict 
those candidate pathways and suggest that many key features 
of HIES are likely caused by IL-6 and IL-11 signaling de-
fects. Similar to STAT3-HIES (Flinn et al., 2016; Miller et al., 
2017), the early lung defects such as bronchiectasis in P1 may 
be caused by recurrent infections, but additional features, such 
phospho-STAT3+ cells based on the unstimulated condition. Gray areas indicate range found in healthy individuals. (A) Levels of STAT3 phosphorylation 
were assessed in T cells (CD3+/CD19− lymphocyte gate) in a whole-blood assay. Analysis was performed on nine healthy donors (HD), patient P1 (p.N404Y), 
the parents of P1, and a patient with a homozygous IL-11RA substitution (p.D297Y). Blood samples of P1 were independently analyzed on two occasions, 
separated by 13 mo. (B) Comparison of phospho-STAT3 levels in T lymphoblasts of two healthy donors (age matched to P1), P1, and the IL-11RA patient, 
which were generated from frozen PBMCs by PHA/IL-2 expansion. Data are a pooled summary result from three independent experiments with one, two, 
and four replicates each. Differences were investigated by Mann-Whitney U test. **, P < 0.01. (C) Assessment of LCLs generated from five healthy donors, P1, 
and the IL-11RA patient. Experiments with LCLs were performed twice, independently. Analysis of primary B cells was performed in the whole-blood assay 
described in A. (D) STAT3 phosphorylation in primary monocytes based on the whole-blood assay described in A. (E–G) Freshly isolated PBMCs were surface 
stained using fluorophore-conjugated antibodies and analyzed by flow cytometry. HD (adult), n = 15; HD (age matched), n = 3; P1 (p.N404Y), mean of two 
technical replicates of two independent measurements. Representative dot blots of P1 (p.N404Y; top) and the age-matched healthy donor (bottom) are 
shown. Bar graphs summarize measurements from several individuals. (E) CD45RA and CCR7 surface expression in CD3+CD4+CD8−CD25− T cells showing 
the percentage of naive (CD45RA+CCR7+) and memory (CD45RA−CCR7+/− central memory/effector memory including CD45RA+CCR7− TEM RA) cells. (F) Dot 
plot presentation and bar graph showing the expression of CCR6 in CD4+CD25− memory T cells as assessed by surface staining. FSC, forward scatter. (G) 
Intracellular cytokine staining for IFN-γ and IL-17A after PMA/ionomycin stimulation of freshly isolated PBMCs showing frequencies of CD4+CD25− mem-
ory T cells. (H) Dot plot presentation showing intracellular IFN-γ and IL-17A after PMA/ionomycin stimulation of two IL-17A–producing single-cell Th cell 
clones prepared from the Th17 cell–enriched memory compartment, analyzed 28 d after isolation and single-cell cloning. Error bars represent mean ± SEM.
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Figure 4. the GP130 p.n404Y variant causes a defective acute phase response, and P1 primary fibroblasts can be rescued by lentiviral trans-
duction of Wt GP130. (A) Cellular and biochemical response to recurrent chest infections and cellulitis in patient GP130 p.N404Y. White blood cell count 
(WBC), neutrophils, CRP, and fibrinogen measurements are shown at different time points. Black/red lines indicate 3rd/97th percentile or lower/upper limit 
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as lung epithelial protective regeneration or increased matrix 
metalloprotease activity, as well as scoliosis, might contribute 
to the extreme phenotype. Staphyloccocal colonization has 
been noted in keratitis lesions as well as in the lung of P1, 
but no candidiasis was noted. Reduced Th17 responses are 
a hallmark of STAT3-HIES, causing impaired immune re-
sponses to Staphylococci with abscesses in skin and lungs, as 
well as chronic mucocutaneous candidiasis (de Beaucoudrey 
et al., 2008; Ma et al., 2008; Milner et al., 2008). The pres-
ence of Th17 cells in P1, but defective T cell differentiation 
in AD-HIES and in human IL21R defects, hints at the differ-
ential contribution of the IL-21–STAT3 axis (Kotlarz et al., 
2014; Ma et al., 2016).
Craniosynostosis and dental abnormalities are a shared 
phenotype of P1, CRS DA patients associated with IL11RA 
mutations (Nieminen et al., 2011; Keupp et al., 2013; Pa-
pachristoforou et al., 2013; Twigg and Wilkie, 2015), and 
AD-HIES caused by STAT3 mutations (Miller et al., 2017) 
but have not been observed in recessive DOCK8 cases 
(Engelhardt et al., 2015). This strongly points to distur-
bance in a shared IL-11/IL-11RA/GP130/STAT3–driven 
process mediating these phenotypes. In contrast, scoliosis, 
a skeletal abnormality present in P1 (p.N404Y), is typ-
ically associated with STAT3-HIES (Grimbacher et al., 
1999a) but not with IL11RA mutations (Nieminen et al., 
2011; Keupp et al., 2013; Papachristoforou et al., 2013). 
Interestingly, common variants in IL6 have been linked to 
scoliosis in genome-wide association studies (Aulisa et al., 
2007; Nikolova et al., 2015). This suggests that abnormal 
IL-11 signaling does not contribute to scoliosis and raises 
the question of whether scoliosis is a primary connective 
tissue phenotype of variants in IL-6 signaling itself or a 
consequence of lung pathology found in HIES caused by 
STAT3 or GP130 defects. Dysplasia of long bones and 
the spine are also associated with rare Stüve-Wiedemann 
syndrome caused by loss-of-function mutations in LIFR 
(Dagoneau et al., 2004; Jung et al., 2010; Mikelonis et 
al., 2014). The preserved LIF signaling in P1 explains 
different clinical manifestations of P1 and patients with 
Stüve-Wiedemann syndrome.
Not surprisingly, IL6ST was predicted to be one of the 
3,110 as yet undiscovered primary immunodeficiency genes 
(Itan and Casanova, 2015). The negative outcome of our ex-
tensive search across several cohorts with STAT3/DOCK8/
PGM3 mutation-negative HIES, covering a combined total 
of over 200 individuals, suggests that immunodeficiency 
caused by genetic defects in GP130 is very rare. Indeed, 
IL6ST has been screened previously as a candidate gene 
for both craniosynostosis (Keupp et al., 2013) and primary 
immunodeficiency (Woellner, 2013) without success. This 
might be explained by the essential role of GP130 in signaling 
pathways such as LIF (or CNTF/CT1/CLC) signaling. The 
high evolutionary constraint pLI score for IL6ST (Fig. 1 E) 
indicates that there is strong negative selection against hetero-
zygous loss-of-function (nonsense or frameshift) mutations. 
We propose that only particular nonsynonymous variants in 
GP130 are viable in the homozygous state, depending on the 
specificity with which they abrogate signaling by different 
cytokines. In line with this hypothesis, the p.N404Y substi-
tution is defective in IL-6, IL-11, IL-27, or OSM signaling 
but confers largely normal LIF signaling. This hypothesis is 
supported by the known activity of LIF, CNTF, CT1, and 
OSM during the early stages of embryonic development 
(Kristensen et al., 2005) and the lethal effects of Lifr KO in 
mice (Ware et al., 1995).
MAtErIALS And MEthodS
case studies
P1 was born at term after normal pregnancy with congen-
ital left hip dislocation. Her birthweight was 2.78 kg (15.1 
percentile according to World Health Organization growth 
charts). Her perinatal period was otherwise uneventful, 
and she received standard vaccinations including Bacillus 
Calmette–Guérin without adverse events. P1 is now 7 yr old.
Skeletal system. An abnormal head shape was noticed by her 
parents from the age of 6 mo. She was diagnosed at 18 mo 
with pansutural craniosynostosis, which required surgery at 
the ages of 2 and 3 yr. Other skeletal malformations included 
congenital contractures of her right elbow, limited finger ex-
of the normal range, respectively. (B) CRI SPR/Cas9-mediated KO of GP130 in human hepatoma Hep3B cells results in absent GP130 surface expression. 
(C) IL-6–mediated production of fibrinogen is GP130 dependent. Hep3B GP130-KO cells were stimulated with IL-6 for 24 h, and expression of the fibrinogen 
α chain (FGA; left) and fibrinogen β chain (FGB; right) was determined by quantitative PCR. Gene expression was determined relative to the housekeep-
ing gene RPLP0 and expressed as fold-induction compared with unstimulated cells. Data represent summary results from four independent experiments 
(mean ± SEM). (D) Hep3B GP130-KO cells were transiently transfected with GP130 WT, GP130 p.N404Y-mutant plasmid, and FGA (left) and FGB (right) 
gene expression was analyzed after 24 h of IL-6 stimulation. Gene expression was determined relative to the housekeeping gene RPLP0 and expressed as 
fold-induction compared with the unstimulated vector control. Data represent pooled results from four independent experiments (mean ± SEM). (E) Fibro-
blasts of a healthy donor and P1 were stimulated with the indicated concentrations (ng/ml) of IL-6, IL-11, IL-27, OSM, and LIF. The levels of phospho-STAT3 
(p-STAT3) were determined after 15-min stimulation by Phosflow. Titration curves are representative of two independent experiments. Curves are fitted by 
nonlinear/linear regression analysis. (F) Healthy donor and patient GP130 p.N404Y fibroblasts were treated as in E, and STAT1 phosphorylation (p-STAT1) 
was analyzed using flow cytometry. Titration curves are representative of two independent experiements. MFI, mean fluorescence intensity. (G) Lentiviral 
transduction of GP130 WT reconstitutes STAT3 phosphorylation in primary fibroblasts with p.N404Y variant. Fibroblasts were stimulated with 30 ng/ml IL-6 
and 50 ng/ml IL-11 for 15 min. Quantification is based on four independent experiments. HD, healthy donor; LV, lentiviral. Differences were determined by 
Mann-Whitney U test. *, P < 0.05.
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tension, and progressive severe scoliosis. Because of congenital 
left hip dislocation, her left lower limb is shortened by 3 cm.
Pulmonary and nonpulmonary systemic infections. Ophthal-
mic infections were reported at the initial and subsequent 
presentations. At the age of 6 mo, P1 started to have recurrent 
chest infections and subsequently developed bronchiectasis of 
her right lung. She had to be hospitalized on several occa-
sions. At the age of 1.5 yr, a transient low-level EBV 
viremia was noted.
At the age of 3.5 yr, she was admitted to the hospi-
tal with sepsis, right tension pneumothorax, and right-sided 
empyema requiring intravenous antibiotics, ventilation, chest 
drain, and intensive care. S. milleri was isolated from the pleu-
ral fluid culture. After multiple infections, her chest radiograph 
showed progressive opacification of her right lung. Consistent 
with a reduced pulmonary functional capacity, she requires 
oxygen supplementation (0.8 liter/min) at night. Bronchos-
copy showed normal airway anatomy, excluding a congenital 
tracheal or bronchial abnormality as an alternative noninfec-
tive explanation for the progressive pulmonary changes. She 
started azithromycin as prophylaxis for her chest infections at 
the age of 4.5 yr, with a good response.
After the second cranial surgery, P1 developed orbital 
cellulitis and severe sepsis, caused by a group A streptococcal 
infection that spread into the central nervous system leading 
to secondary superior sagittal sinus thrombosis and left-sided 
middle cerebral artery territory venous infarct associated with 
a right-sided hemiplegia. During all reported infectious epi-
sodes, P1 never developed a fever.
Skin infections. From the age of 2 yr, P1 suffered from ec-
zema with extensive excoriated lesions and secondary skin 
infections. She is on regular antihistamines and topical treat-
ment with acceptable control.
neurological. P1 has mild to moderate cognitive and motor 
delay. She started to walk at the age of 2 yr and spoke a few 
three-word phrases at the age of 5.5 yr. Secondary to the 
middle cerebral artery territory infarct, she suffers from spas-
ticity of the right upper limb and increased tone in the right 
lower leg. There is no history of cramps.
case study IL-11rA p.d297Y. The patient was diagnosed with 
CRS DA caused by a previously unpublished homozygous 
c.889G>T (p.D297Y) mutation in IL11RA. Because of 
multi-suture craniosynostosis, he required posterior vault ex-
pansion for raised intracranial pressure at 5 yr of age and 
underwent monobloc midfacial advancement. The patient is 
now 15 yr old.
clinical studies
The clinical studies were approved by Oxfordshire Research 
Ethics Committee B (reference C02.143) and the Lon-
don Riverside Research Ethics Committee (reference 09/
H0706/20). Subjects were enrolled into the craniosynostosis 
cohort based on referral from a craniofacial unit or clinical 
genetics department, with craniosynostosis proven on either 
plain radiographs or computed tomography of the skull.
DNA was extracted from venous blood collected into 
EDTA, LCLs, or cultured fibroblasts established from skin bi-
opsies. All DNA was extracted using the Nucleon Blood and 
Cell Culture DNA extraction kit (Gen-Probe Inc.) according 
to the manufacturer’s instructions.
Healthy volunteer donors were recruited as part of the 
Oxford Gastrointestinal Illness Biobank (REC 11/YH/0020) 
or obtained as leukocyte cones from the UK blood donor 
bank. Informed consent for participation in this study was 
obtained from healthy donors, patients, or their parents.
Exome and genome sequencing
3 µg of genomic DNA from P1 was captured using a TruSeq 
kit (v.2; Illumina) and sequenced on a HiSeq2000 platform 
(Illumina). Reads were mapped with Novoalign (Novocraft 
Technologies), and variants were called using SAMtools 
(v0.1.19) and annotated using ANN OVAR (Wang et al., 
2010). Homozygous variants (called if variant reads accounted 
for >80% of total reads; total 477) were prioritized by restrict-
ing analysis to changes with greater than four variant read 
calls, in coding regions only, that were predicted to change 
the amino acid sequence (total of 49 variants; Table S1). The 
cDNA numbering for the IL6ST variant identified is based 
on transcript NCBI RefSeq accession no. NM_002184/
Ensembl accession no. ENST00000381298.6, beginning at 
the ATG start codon. Exome- and genome-sequencing data 
from 35 patients from 25 families with HIES phenotype were 
screened for mutations in IL6ST. These individuals had been 
referred for HIES with atopy, elevated serum IgE, and con-
nective-tissue or skeletal abnormalities and were STAT3 WT.
targeted and Sanger sequencing
Resequencing of IL6ST (covering all 18 exons) in 467 sub-
jects with craniosynostosis (negative for mutations in the 
major causative genes) was performed using either the Access 
Array integrated fluidic circuit system (Fluidigm) or molec-
ular inversion probes (O’Roak et al., 2012) followed by anal-
ysis on the Ion PGM system (Life Technologies Ltd). Sanger 
sequencing was performed using standard protocols. Primer 
sequences and PCR amplification conditions are available on 
request. Immunodeficiency patients (HIES and mucocuta-
neous candidiasis; 207 subjects) were screened using HIES/
chronic mucocutaneous candidiasis panels based on HaloPlex 
(Agilent) and MiSeq (Illumina) technologies.
cell purification and culture
Hep3B cells were obtained from the European Collection 
of Authenticated Cell Cultures and maintained in DMEM 
(Sigma- Aldrich) supplemented with 10% FCS. HEK293 were 
cultured in DMEM supplemented with 10% FCS. Primary 
human skin fibroblasts from a healthy individual (GM05659) 
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were obtained from Coriell Cell Repositories and cultured 
in DMEM with 10% FCS. Primary fibroblasts from P1 were 
generated from a skin biopsy. PBMCs were isolated by density 
gradient centrifugation (Lymphoprep; StemCell Technolo-
gies, Inc.) and cultured in RPMI1640 medium with gluta-
mine (Sigma-Aldrich) supplemented with 10% FCS. LCLs 
from patients and five healthy donors were generated from 
PBMCs with supernatant from the EBV-producing marmo-
set cell line B95-8 according to standard protocols. LCLs were 
cultured in RPMI medium with 10% FCS. Th cell subsets 
were FACS sorted according to the following surface marker 
expression: CD3+CD4+CD8−CD25−CD45RA−CCR7+/− 
including CD45RA+CCR7− effector memory CD45RA- 
expressing T cells TEM RA (total memory T cells) and CD3+ 
CD4+CD8−CD25−CD45RA−CCR7+/−CXCR3−CCR6+ 
CCR4+ including CD45RA+ CCR7− TEM RA (enriched in 
Th17 cells). Cell sorting was performed using a FAC SAria 
III flow cytometer (BD Biosciences). Flow cytometry data 
were analyzed with FlowJo software (Tree Star). T lympho-
blasts were generated from FACS-sorted CD4+ memory T 
cells (CD3+CD4+CD25−CD45RA−CCR7+/− including 
CD45RA+CCR7− TEM RA) and expanded with 1 µg/ml 
PHA (Gibco), 500 U/ml IL-2 (supernatant of the IL2T6 
line), and irradiated allogenic feeder cells. T cells were cul-
tured in RPMI1640 medium with glutamine (Sigma- 
Aldrich) supplemented with 5% human serum (NHS Blood 
Center Oxford), 1% sodium-pyruvate (Gibco), 1% non-
essential amino acids (Gibco), 1% penicillin/streptomycin 
(Gibco), and 50 µM β-mercaptoethanol (Sigma-Aldrich). 
The following antibodies for FACS sorting were used: anti- 
CD3–PE/Dazzle 594 (clone UCHT1; Biolegend), anti- 
CD4–BV510 (clone OKT4; Biolegend), anti-CD8–AF700 
(clone SK1; Biolegend), anti-CD25–AF647 (clone M-A251; 
Biolegend), anti-CD45RA–BV650 (clone HI100; Bio-
legend), anti-CCR7–BV421 (clone G043H7; Biolegend), 
anti-CD14–APC (clone 18D11; ImmunoTools), anti-CD19–
APC (clone LT19; ImmunoTools), and anti-CD56–APC 
(clone MEM-188; ImmunoTools).
Ex vivo t cell phenotyping
The expression of surface markers was analyzed by staining 
for 15 min at room temperature in PBS supplemented with 
0.5% (vol/vol) human serum. For the exclusion of dead cells 
during the analysis, cells were stained before fixation using 
Fixable Viability Dye eFluor 780 (eBioscience) according to 
the manufacturer’s instructions. The following fluorophore- 
conjugated antibodies were used for analysis: anti-CD3 
(clone UCHT1; BD Biosciences), anti-CD4 (clone RPA-T4; 
Biolegend), anti-CD8 (clone SK1; Biolegend), anti-CD14 
(clone M5E2; Biolegend), anti-CD19 (clone SJ25C1; BD 
Biosciences), anti-CD25 (clone MA-A251; Biolegend), 
anti- CD45RA (clone HI100; Biolegend), anti-CD56 (clone 
NCAM16.2; BD Biosciences), anti-CD127 (clone A019D5; 
Biolegend), anti-CCR4 (clone 1G1; BD Biosciences), anti- 
CCR6 (clone G034E3; Biolegend), anti-CCR7 (clone 
G043H7; Biolegend), anti-CCR9 (clone L053E8; Bioleg-
end), anti-CCR10 (clone 314305; R&D), anti-CXCR3 
(clone 1C6; BD Biosciences), anti-CXCR5 (clone J252D4; 
Biolegend), and anti-CRTh2 (clone BM16; BD Biosciences).
For intracellular cytokine staining, cells were stimulated 
for 5 h with 0.2 µM PMA (cat. no. P8139; Sigma-Aldrich) 
and 1 µg/ml ionomycin (cat. no. I0634; Sigma-Aldrich) in 
the presence of 10 µg/ml brefeldin A (cat. no. B7651; Sigma- 
Aldrich) for the final 2.5 h of culture. Cells were fixed and 
permeabilized with Cytofix/Cytoperm (BD Biosciences) 
according to the manufacturer’s instructions. For the ex-
clusion of dead cells during the analysis, cells were stained 
before fixation using Fixable Viability Dye eFluor 780 ac-
cording to the manufacturer’s instructions. The following 
fluorophore-conjugated anti-cytokine antibodies were used 
for analysis: anti–IL-4 (clone MP4-25D2; BD Biosciences), 
anti–IL-10 (clone JES3-9D7; eBioscience), anti–IL-13 (clone 
85BRD; eBioscience), anti–IL-17A (clone eBio64DEC17; 
eBioscience), anti–IFN-γ (4S.B3; Biolegend), and anti-TNF 
(clone MAb11; Biolegend). Flow cytometry data were ana-
lyzed with FlowJo software.
t cell single-cell cloning
Single T cell clones were generated by limiting dilution in 
384-well plates (Corning) using 1 µg/ml PHA (Gibco) and 
2.5 × 104 irradiated allogeneic (45 Gy) PBMCs per well. 
After 14 d of culture, single-cell clones were transferred to 
96-well U-bottom plates and further expanded for a total of 
21–28 d in IL-2–containing medium (500 U/ml; supernatant 
of IL2T6 line). The IL2T6 cell line was provided by F. Sallusto 
(Università della Svizzera italiana, Bellinzona, Switzerland; 
and ETH Zurich, Zurich, Switzerland).
cytokine stimulation
Cells were stimulated with the indicated concentrations 
(ng/ml) of recombinant human IL-6, IL-21, IL-22, IL-27, 
OSM, LIF, IFN-γ, FGF-basic, and epidermal growth fac-
tor (all Peprotech) and IL-10, IL-11, and universal type 
I IFN Protein (all R&D).
Generation of hEK293 and hep3B GP130-Ko cell lines
HEK293 and Hep3B GP130 KO cell lines were generated 
using CRI SPR/Cas9 following published protocols (Ran et 
al., 2013). Guide RNA sequences were designed with the 
CRI SPR Design tool (Massachusetts Institute of Technol-
ogy) and cloned into pSpCas9(BB)-2A-GFP (PX458), which 
was a gift from F. Zhang (Massachusetts Institute of Technol-
ogy, Cambridge, MA; plasmid no. 48138; Addgene). Guide 
RNA clones were verified by sequencing (target sequences: 
5′-GGA CCA AAG ATG CCT CAA CT-3′ or 5′-GTT TAG 
GAT TCG CTG TAT GA-3′). The resulting plasmid was trans-
fected with Lipofectamine 2000 in HEK293 and Hep3B 
cells. Cells were expanded and subsequently FACS sorted 
for the GP130-absent cell population. FACS-sorted Hep3B 
cells were subjected to single-cell cloning by limiting dilution 
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and plated in 384-well plates together with irradiated feeder 
cells from a naive Hep3B cell line. Clones were screened for 
absence of GP130 surface expression using flow cytometry. 
Dideoxy sequencing of FACS-sorted/cloned cells confirmed 
disruption of GP130 coding sequences (Fig. S1 C). Staining 
of surface GP130 was performed with anti-GP130–biotin 
(AN G30; eBioscience) followed by staining with appropriate 
streptavidin-conjugated fluorochromes.
Plasmid and lentivirus generation
Sequences encoding WT or mutant GP130, IL-6RA, or IL-
11RA were cloned into the pcDNA3.1(+) vector without 
C- or N-terminal tags (GenScript). Sequences were verified 
by Sanger sequencing after each transformation step. The WT 
IL6ST gene was custom cloned into pLEN TI7.3V5-DEST 
(Geneart; Thermo Fisher). Supernatant containing lentivirus 
particles was generated from HEK293T cells cotransfected 
with expression vector and packaging plasmids pMD2.G and 
psPAX2 using Fugene 6 (Promega). Supernatants were filtered 
through a 0.45-µm filter and added to primary fibroblasts 
from P1 cultured in 6-well plates. The transduction efficiency 
of fibroblasts based on expression of EmGFP was ∼70%.
Phosflow StAt3 and StAt1 signaling assay
Unless indicated otherwise, phosphorylation of STAT1 or 
STAT3 transcription factors was determined by Phosflow after 
15 min of cytokine stimulation. Analysis of primary blood 
lymphocytes and monocytes was performed in whole blood. 
Cells were stained with different combinations of the follow-
ing antibodies: anti-CD19–FITC (clone HIB19; Biolegend), 
anti-CD19–BV711 (clone HIB19; Biolegend), anti-CD14–
BV650 (clone M5E2; Biolegend), anti-CD3–BV711 (clone 
UCHT1; BD biosciences), and anti-CD3–PE-Cy5 (clone 
UCHT1; Biolegend). Cells were subsequently activated with 
100 ng/ml IL-6, 50 ng/ml IL-10, 100 ng/ml IL-21, or 100 
ng/ml IL-27 before immediate fixation and lysis of red blood 
cells (BD biosciences). For analysis of STAT3 phosphorylation 
in T lymphoblasts, cells were extensively washed and rested 
in complete medium without IL-2 for 2 h before activation 
with 100 ng/ml IL-6, 50 ng/ml IL-10, 100 ng/ml IL-21, or 
100 ng/ml IL-27. Levels of phospho-STAT3 in LCLs were 
determined in serum-starved cells, stimulated with 50 ng/
ml IL-6 or 50 ng/ml IL-21 before resuspending cells in Cy-
tofix buffer (BD biosciences). To determine the effect of dif-
ferent concentrations of GP130-family cytokines, HEK293 
GP130-KO cells were plated in 24-well plates and tran-
siently transfected with empty plasmid or plasmid encoding 
WT or mutant GP130 using Lipofectamine 2000 (Thermo 
Fisher). Cells were cotransfected with IL-6RA or IL-11RA 
to enhance phosphorylation signal and with GFP to allow 
gating on successfully transfected cells. 24  h after transfec-
tion, cells were serum starved for 2 h, followed by stimula-
tion with the indicated cytokines at different concentrations 
and immediate detachment with trypsin-EDTA solution and 
fixation in Cytofix buffer. Similarly, fibroblasts plated in 12-
well plates were stimulated with IL-6–family cytokines at 
different concentrations, immediately detached with trypsin- 
EDTA solution, and resuspended in Cytofix buffer. After 
fixation, primary cells, LCLs, and cell lines were washed in 
PBS, permeabilized with ice-cold Perm Buffer III (BD bio-
sciences), and stained with anti-STAT3 (pY705)–Alexa Fluor 
647 (clone 4/P-STAT3) and anti-STAT1 (pY701)–BV421 or 
Alexa Fluor 488 (clone 4a; both BD biosciences) at room 
temperature. Samples were acquired on an LSR II or LSR-
Fortessa flow cytometry system, and data were analyzed with 
FlowJo software (version 10.0.6).
Immunofluorescence and confocal microscopy
HEK293 GP130-KO cells were seeded on poly-l-lysine–
coated 8-well chamber slides (Sarstedt) and transiently trans-
fected with empty control plasmid or plasmid encoding 
WT or mutant GP130 using Lipofectamine 3000 (Thermo 
Fisher). The next day, cells were rested in serum-free medium 
for 1 h and activated with 0.5 ng/ml IL-6 for 15 min. After 
fixation with 2% paraformaldehyde, cells were permeabilized 
with ice-cold methanol for 10 min before staining with anti- 
STAT3 (no. 12640; Cell Signaling) and appropriate secondary 
antibody (Alexa Fluor 568 goat anti–rabbit IgG; Life Tech-
nologies). Cell nuclei were counterstained with DAPI, and 
slides were mounted with Vectashield mounting medium 
(Vector Laboratories). Images were acquired with an inverted 
confocal microscope (510; ZEN2009 software; Zeiss) and an-
alyzed with ImageJ software (National Institutes of Health; 
Schindelin et al., 2012). For illustration of STAT3 nuclear 
translocation in HEK293 cells, images were processed by 
Photoshop (CS4; Adobe).
Luciferase StAt3 reporter assay
The dual-luciferase STAT3 reporter assay was obtained from 
Qiagen. HEK293 GP130-KO cells were transiently trans-
fected with WT or mutant GP130-expressing plasmids in 
multiple replicates of an opaque white 96-well plate with 
Lipofectamine 3000 following the manufacturer’s proto-
col. To assess cytokine signaling, HEK293 GP130-KO cells 
were cotransfected with IL-6RA and IL-11RA expression 
vectors. After 24 h, cells were rested in serum-free medium 
for 2 h followed by stimulation with 0.5 ng/ml recombinant 
human IL-6 or 1 ng/ml IL-11 for 6 h. Cells were lysed di-
rectly in opaque 96-well plates, and luminescent signal from 
Firefly and Renilla reporter genes was quantified with the 
Dual- Glo Luciferase Assay system (Promega) according to the 
manufacturer’s instructions on a FLUOstar OPT IMA plate 
reader (BMG labtech). Data were normalized to the activ-
ity of Renilla luciferase.
Quantitative Pcr mrnA expression
Quantitative PCR was performed according to established 
standard protocols. Total RNA was extracted from cells using 
the RNeasy mini kit (Qiagen), and cDNA was synthesized 
using the High Capacity cDNA Reverse Transcription kit 
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(Applied Biosystems). Gene expression was determined using 
Taqman assays from Applied Biosystems: fibrinogen α chain 
(Hs00241027_m1), fibrinogen β chain (Hs00170586_m1), 
and RPLP0 (Hs99999902_m1). For induction of acute phase 
genes, Hep3B GP130-KO cells were stimulated with 50 ng/
ml IL-6 for 24  h in complete medium. Transient transfec-
tion with GP130 WT or variant plasmid or empty vector 
was performed 24 h before stimulation using Lipofectamine 
2000. Results were normalized to the housekeeping gene 
RPLP0 and expressed as fold-induction compared with the 
unstimulated condition.
Modeling of mutations
All protein structures were analyzed and rendered in PyMol 
(version 1.4; DeLano Scientific). Coordinate files were obtained 
from the Protein Data Bank (PDB; accession no. 1P9M for 
IL-6/IL-6RA/GP130; accession no. 3L5H for GP130 D1-D6).
Protein sequence alignment
Multiple sequences were aligned using ClustalW2 (Goujon et al., 
2010). Data were obtained from NCBI. Sequence alignment is 
based on the following RefSeq accession nos.: NP_001106976.1, 
NP_001124412.1, NP_990202.1, NP_034690.3, NP_002175.2, 
NP_004834.1, NP_000751.1, NP_002301.1, NP_003990.1, 
NP_005526.1, and NP_001550.1.
Statistical analysis
Results were analyzed with Prism (version 5.00; GraphPad 
software, Inc.). Significance of differences was determined by 
two-sided Mann-Whitney U tests, and p-values <0.05 were 
considered significant.
online resources
The following online data sources have been accessed: 1000 
Genomes, dbSNP, GenBank, gnomAD, PolyPhen, SIFT, 
STR ING, ExAC browser, GDI-server, and COS MIC.
online supplemental material
Fig. S1 shows the generation and functional consequences of 
CRI SPR/Cas9-mediated GP130-KO. Fig. S2 shows struc-
tural analysis of the GP130 p.N404Y substitution. Table S1 
lists homozygous nonsynonymous variants in P1 identified 
by exome sequencing.
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